Tobacco-Related Disorders center on nicotine dependence via a legal, widely available combustible or vaporized product, with a well-characterized Use Disorder and Withdrawal syndrome; Inhalant-Related Disorders center on volatile household or industrial chemicals misused for their rapid intoxicating effect, with serious acute organ-toxicity risk and no defined withdrawal syndrome.
Tobacco use often begins in adolescence via socially available cigarettes or vaping products; inhalant use is also often adolescent-onset but is driven specifically by the accessibility and low cost of common household products, sometimes even younger in onset than tobacco.
Tobacco Use Disorder follows a chronic course with a well-defined withdrawal syndrome that can persist for weeks; inhalant use tends to follow a more episodic pattern in many users, with acute intoxication resolving within minutes and no defined withdrawal syndrome to sustain a comparable dependence cycle.
Tobacco Use is associated with cardiovascular and pulmonary disease risk over years of use; Inhalant use is associated with acute risks including sudden cardiac death, as well as chronic neurotoxicity and organ damage (liver, kidney, bone marrow) with sustained heavy use.
Both cause significant impairment, but on different timescales: tobacco's impairment accrues chronically over years, while inhalants carry meaningful acute mortality risk even from a single use episode, a starkly different impairment profile.
Neither diagnosis is made from an isolated, non-impairing exposure; a key structural point is that neither Tobacco-Related Disorders (no Intoxication category) nor Inhalant-Related Disorders (no Withdrawal category) has the full Intoxication/Withdrawal/Use Disorder triad that most other substance categories have.
The differential-defining structural teaching point is that these two substance categories are each missing a different piece of the typical diagnostic triad -- tobacco lacks a defined Intoxication diagnosis, while inhalants lack a defined Withdrawal diagnosis -- making this pairing a useful contrast in how DSM-5-TR tailors diagnostic categories to each substance's actual clinical presentation.
Learners often assume all substance categories share the same three-part diagnostic structure; this pairing highlights two different, substance-specific exceptions to that assumption.
A patient who reports strong cigarette cravings, irritability, and difficulty concentrating a day after their last cigarette fits nicotine withdrawal, a well-defined diagnosis; a patient found disoriented with a chemical odor after using an aerosol product fits inhalant intoxication, but if they later report no distinct 'withdrawal' symptoms after stopping, that is consistent with inhalants lacking a defined withdrawal category.
| Feature | Tobacco-Related Disorders | Inhalant-Related Disorders |
|---|---|---|
| Missing category | Tobacco: no Intoxication diagnosis | Inhalants: no Withdrawal diagnosis |
| Primary risk timescale | Chronic (years of cardiovascular/pulmonary risk) | Acute (cardiac risk even on first use) |
| Typical adolescent accessibility | High (legal purchase age restrictions) | Very high (common household products) |
A problematic pattern of tobacco/nicotine use leading to clinically significant impairment or distress, evidenced by at least 2 of 11 characteristic indicators within a 12-month period, with a recognized withdrawal syndrome (irritability, frustration/anger, anxiety, difficulty concentrating, increased appetite, restlessness, depressed mood, insomnia) distinct from, but using the same diagnostic framework as, other substance use disorders.
A category covering problematic use of, and intoxication from, volatile hydrocarbon-based substances (such as glues, aerosols, paint thinners, and fuels) inhaled for their psychoactive effects, distinguished from other substance classes by the specific substances involved and their acute and potentially serious toxic effects.